Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Biocides; animal or insect repellents or attractants
Reexamination Certificate
2005-01-18
2005-01-18
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Biocides; animal or insect repellents or attractants
C424S400000, C424S070100, C514S031000
Reexamination Certificate
active
06844004
ABSTRACT:
The present invention relates to formulations of Pimaricin (also called Natamycin), that are useful for the treatment and suppression of topical infections such as those caused by various pathogens including molds and yeast, that are resistant to azole compounds and to Amphotericin B. Methods for treatment of infections are also set forth.
REFERENCES:
patent: 3343958 (1967-09-01), Morse
patent: 3343968 (1967-09-01), Huhtanen
patent: 3892850 (1975-07-01), Struyk et al.
patent: 4148891 (1979-04-01), Smink
patent: 4536494 (1985-08-01), Carter
patent: 4600706 (1986-07-01), Carter
patent: 4766046 (1988-08-01), Abra et al.
patent: 4794117 (1988-12-01), Corbiere
patent: 4883785 (1989-11-01), Chow et al.
patent: 4950477 (1990-08-01), Schmitt et al.
patent: 5006595 (1991-04-01), Smith et al.
patent: 5277914 (1994-01-01), Szoka, Jr.
patent: 5430057 (1995-07-01), Andersson et al.
patent: 5552151 (1996-09-01), Noordam et al.
patent: 5559148 (1996-09-01), Andersson et al.
patent: 5651991 (1997-07-01), Sugiyama
patent: 5821233 (1998-10-01), Van Rijn et al.
patent: 5858410 (1999-01-01), Muller et al.
patent: 5877205 (1999-03-01), Andersson
patent: 6045815 (2000-04-01), Andersson et al.
patent: 6107333 (2000-08-01), Andersson
patent: 6239113 (2001-05-01), Dawson et al.
patent: 6291500 (2001-09-01), Ponikau
patent: 6369036 (2002-04-01), Van Rijn et al.
patent: 6406713 (2002-06-01), Janoff et al.
patent: 20020177562 (2002-11-01), Weickert et al.
patent: 3819504 (1989-12-01), None
patent: 0664130 (1995-07-01), None
patent: 2106498 (1983-04-01), None
patent: 2116425 (1983-09-01), None
patent: WO 9307884 (1993-04-01), None
patent: WO 9629998 (1996-10-01), None
Hansen et al., “Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill,”J. Immunol. Methods, 119:203-210, 1989.
Korteweg et al., “Some pharmacological properties of Pimaricin and possible clinical application of this antifungal antibiotic,”Iind int. Symp. Chemotherapy, 11:261-272, 1963.
Lavingia and Dave, “Comparative study of amphotericin B Pimaricin and Gentian violet on ocular fungi,”Indian J. Ophalmol., 34:73-77, 1986.
Masterton et al., “Natamycin in genital candidosis in men,”Br. J. Vener. Dis., 51(3):210-212, 1975.
Mulligan and McCauley, “Factors that influence the determination of residual solvents in pharmaceuticals by automated static headspace sampling coupled to capillary GC-MS,”J. Chromatogr. Sci., 33:49-54, 1995.
Raab, “Natamycin (Pimaricin) its properties and Possibilities in medicine,” 1-134, Georg Thieme Publishers Stuttgart, 1972.
Sawyer et al., “Miconazole: a review of its antifungal activity and therapeutic efficacy,”Drugs, 9(6):406-423, 1975.
Shah et al., “Microsphaeropsis olivacea keratitis and consecutive endophthalmitis,”Am. J. of Ophthalmology, 131:142-143, 2001.
Spiegel and Noseworthy, “Use of nonaqueous solvents in parental products,”J. Pharm. Sci., 52:917-927, 1963.
Struyk et al., “Pimaricin, a new antifungal antibiotic,”Antibiot. Ann., 878-885, 1957-1958.
Yalkowsky and Roseman, “Solubilization of drugs by cosolvents,” In:Techniques of solubilization of drugs, Yalkowsky (Ed.), 91-134, Marcel Dekker Inc., NY, NY, 1981.
Anaissie et al., “Emerging fungal pathogens,”Eur. J. Clin. Microbiol. Infect. Dis.,8:323-330, 1989.
Anaissie et al., “Fluconazole susceptibility testing ofCandida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading,”Antimicrob. Methods Chemother., 35:1641-1646, 1991.
Andersson et al., “KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts,”Leukemia, 9:2100-2108, 1995.
Andersson et al., “Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs,”Cancer Chemother. and Pharmacol., 38:406-416, 1996.
Andersson et al., “Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern,”Cancer Genetics and Cytogenet., 24:335-343, 1987.
Christensen and Bush, “Vaginalcandida albicanstreated with three different concentrations of natamycin (Pimafucin) for 6 days,”Acta Obstet Gynecol Scand, 61:325-328, 1982.
Drug Facts and Comparisons, Wolters Kluwer Co., St. Louis, MO, Intravenous Nutritional Therapy, p. 138, 1977.
Drug Information for Health Care Professional: USPDI-Natamycin, p. 1705, 1989.
Gallagher et al., “Characterization of the continuous differentiation myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia,”Blood, 54:713-73, 1979.
Kajda, “Local treatment of chronic paranoychia with pimaricin-dimethyl-sulfoxide (DMSO) suspension,” Abstract No. 35097, Chemical Abstracts, 79:No. 6, Columbus, Ohio, 1973.
Board of Regents , The University of Texas System
Fulbright & Jaworski LLP
Page Thurman K.
LandOfFree
Topical formulations of natamycin/pimaricin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical formulations of natamycin/pimaricin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical formulations of natamycin/pimaricin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409581